Vyome Holdings (HIND) Other Accumulated Expenses (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Other Accumulated Expenses of $227766.0 for Q1 2026, up 384.61% year-over-year from $47000.0 in Q1 2025, and down 7.02% quarter-over-quarter from $244974.0 in Q4 2025.
Vyome Holdings (HIND) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
Vyome Holdings' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $227766.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 384.61% year-over-year to $227766.0; the TTM figure through Mar 2026 stood at $227766.0 (up 384.61% YoY), while the FY2025 annual figure was $244974.0, up 126.96% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $227766.0, down from $244974.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $491000.0 in Q4 2022, with the low at $45000.0 in Q3 2024.
- The 5-year median for Other Accumulated Expenses is $105000.0 (2023), against an average of $155993.0.
- The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses sank 88.19% in 2023, then jumped 384.61% in 2026.
- Vyome Holdings' Other Accumulated Expenses stood at $491000.0 in 2022, then tumbled by 88.19% to $58000.0 in 2023, then surged by 86.1% to $107937.0 in 2024, then jumped by 126.96% to $244974.0 in 2025, then fell by 7.02% to $227766.0 in 2026.
- Business Quant data shows HIND's Other Accumulated Expenses at $227766.0 in Q1 2026, $244974.0 in Q4 2025, and $93204.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107,660.00 |
| Mar 31, 2026 | 227,766.00 |
| Dec 31, 2025 | 244,974.00 |
| Sep 30, 2025 | 93,204.00 |
| Jun 30, 2025 | 54,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | 107,937.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 56,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 105,000.00 |
| Jun 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 345,000.00 |
| Dec 31, 2022 | 491,000.00 |
| Sep 30, 2022 | 115,000.00 |
| Jun 30, 2022 | 222,000.00 |
| Mar 31, 2022 | 299,000.00 |
| Dec 31, 2021 | 185,000.00 |
| Sep 30, 2021 | 359,000.00 |